Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo

See Hyoung Park, Young Min Chung, Jessica Ma, Qin Yang, Jonathan S. Berek, Mickey C.T. Hu

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer. Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that bepridil (BPD) and trifluoperazine (TFP), which are FDA-approved drugs for treatment of schizophrenia and angina respectively, inhibit Akt-pS473 phosphorylation and promote FOXO3 nuclear localization and activation in TNBC cells. BPD and TFP inhibit survival and proliferation in TNBC cells and suppress the growth of TNBC tumors, whereas silencing FOXO3 reduces the BPD- and TFP-mediated suppression of survival in TNBC cells. While BPD and TFP decrease the expression of oncogenic c-Myc, KLF5, and dopamine receptor DRD2 in TNBC cells, silencing FOXO3 diminishes BPD- and TFP-mediated repression of the expression of these proteins in TNBC cells. Since c-Myc, KLF5, and DRD2 have been suggested to increase cancer stem cell-like populations in various tumors, reducing these proteins in response to BPD and TFP suggests a novel FOXO3-dependent mechanism underlying BPD- and TFP-induced apoptosis in TNBC cells.

Original languageEnglish
Pages (from-to)42110-42125
Number of pages16
Issue number27
StatePublished - Jul 5 2016


  • FOXO3
  • bepridil
  • breast cancer
  • dopamine receptor
  • trifluoperazine


Dive into the research topics of 'Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo'. Together they form a unique fingerprint.

Cite this